Joaquin Duato Sells 40,000 Shares of Johnson & Johnson (JNJ) Stock
Johnson & Johnson (NYSE:JNJ) insider Joaquin Duato sold 40,000 shares of the firm’s stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $144.36, for a total transaction of $5,774,400.00. Following the transaction, the insider now owns 112,848 shares of the company’s stock, valued at $16,290,737.28. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Shares of NYSE JNJ traded up $0.04 during midday trading on Friday, reaching $145.34. 5,343,128 shares of the stock were exchanged, compared to its average volume of 7,921,995. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.72 and a quick ratio of 1.40. Johnson & Johnson has a 52-week low of $118.62 and a 52-week high of $148.32. The company has a market cap of $388.35 billion, a PE ratio of 18.21, a price-to-earnings-growth ratio of 2.26 and a beta of 0.58.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.03 by $0.02. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The business had revenue of $20.35 billion for the quarter, compared to analysts’ expectations of $20.05 billion. During the same period last year, the company earned $1.90 earnings per share. The company’s quarterly revenue was up 3.6% on a year-over-year basis. On average, analysts anticipate that Johnson & Johnson will post 8.16 EPS for the current year.
JNJ has been the subject of several recent research reports. Raymond James raised their target price on shares of Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a report on Wednesday, October 17th. Credit Suisse Group raised their target price on shares of Johnson & Johnson from $149.00 to $152.00 and gave the company an “outperform” rating in a report on Wednesday, October 17th. Citigroup raised their target price on shares of Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a report on Monday, October 22nd. ValuEngine upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Saturday, July 28th. Finally, Wells Fargo & Co restated an “outperform” rating and set a $160.00 target price (up from $155.00) on shares of Johnson & Johnson in a report on Wednesday, October 17th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $142.54.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Selective Wealth Management acquired a new position in Johnson & Johnson during the third quarter valued at approximately $105,000. Financial Gravity Wealth Inc. acquired a new position in Johnson & Johnson during the first quarter valued at approximately $105,000. CSat Investment Advisory L.P. acquired a new position in Johnson & Johnson during the second quarter valued at approximately $107,000. WP Advisors LLC acquired a new position in Johnson & Johnson during the second quarter valued at approximately $108,000. Finally, FNY Investment Advisers LLC acquired a new position in Johnson & Johnson during the second quarter valued at approximately $117,000. 66.60% of the stock is currently owned by institutional investors and hedge funds.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: Leveraged Buyout (LBO) Explained
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.